AU1734401A - Carboxyamido derivatives - Google Patents

Carboxyamido derivatives

Info

Publication number
AU1734401A
AU1734401A AU17344/01A AU1734401A AU1734401A AU 1734401 A AU1734401 A AU 1734401A AU 17344/01 A AU17344/01 A AU 17344/01A AU 1734401 A AU1734401 A AU 1734401A AU 1734401 A AU1734401 A AU 1734401A
Authority
AU
Australia
Prior art keywords
carboxyamido
derivatives
carboxyamido derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17344/01A
Inventor
Ryoichi Ando
Keiichi Aritomo
Kenichi Saito
Aya Shoda
Fumiaki Uehara
Kazutoshi Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Mitsubishi Tokyo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tokyo Pharmaceuticals Inc filed Critical Mitsubishi Tokyo Pharmaceuticals Inc
Publication of AU1734401A publication Critical patent/AU1734401A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU17344/01A 1999-12-09 2000-12-08 Carboxyamido derivatives Abandoned AU1734401A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11/350413 1999-12-09
JP35041399 1999-12-09
PCT/JP2000/008690 WO2001042224A1 (en) 1999-12-09 2000-12-08 Carboxyamido derivatives

Publications (1)

Publication Number Publication Date
AU1734401A true AU1734401A (en) 2001-06-18

Family

ID=18410336

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17344/01A Abandoned AU1734401A (en) 1999-12-09 2000-12-08 Carboxyamido derivatives

Country Status (2)

Country Link
AU (1) AU1734401A (en)
WO (1) WO2001042224A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216314A1 (en) * 2000-10-12 2002-04-22 Scott A Henderson Heterocyclic angiogenesis inhibitors
EP1295885A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
PL370349A1 (en) * 2001-09-21 2005-05-16 Sanofi-Aventis Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
CN101010312B (en) * 2004-06-25 2011-04-20 詹森药业有限公司 Quaternary salt CCR2 antagonists
ATE474833T1 (en) * 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
BRPI0709612A2 (en) 2006-03-15 2011-07-19 Wyeth Corp compound of formula i; method for treating a central nervous system disorder related or affected by the histamine-3 receptor in a patient in need of this treatment; method for h3 receptor inhibition; pharmaceutical composition; and process for the preparation of a compound of formula i
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
CA2649913A1 (en) * 2006-05-19 2007-11-29 Wyeth N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
PE20081152A1 (en) 2006-10-06 2008-08-10 Wyeth Corp N-SUBSTITUTED AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS
CA2693138A1 (en) 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
US8853406B2 (en) 2007-08-06 2014-10-07 Janssen Pharmaceutica Nv Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Inhibitors of the interaction between mdm2 and p53
US8541442B2 (en) 2009-02-04 2013-09-24 Janssen Pharmaceutica N.V. Indole derivatives as anticancer agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57149277A (en) * 1981-03-10 1982-09-14 Taiho Yakuhin Kogyo Kk Heterocyclic compound
IT1250629B (en) * 1991-07-04 1995-04-21 Boehringer Ingelheim Italia USE OF BENZIMIDAZOLIN-2-OXO-1-CARBOXYLIC ACID DERIVATIVES.
GB9726695D0 (en) * 1997-12-17 1998-02-18 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
WO2001042224A1 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
AU6314900A (en) Biarylurea derivatives
AU6714700A (en) Cyclopropylindole derivatives
AU1173201A (en) Skin-gripper
AU3092999A (en) Digital-timeshare-exchange
AU2678800A (en) Modified calycins
AU1734401A (en) Carboxyamido derivatives
AU7319800A (en) 4-oxybenzopyran derivative
AU7952800A (en) 2-alkoxybenzene derivatives
AU5429000A (en) Novel bicyclonucleoside derivatives
AU3670000A (en) Novel thiazolobenzimidazole derivatives
AU5967600A (en) Candystraw
AU7453900A (en) 4-oxybenzopyran derivative
AU6335000A (en) Depthimeter
AU4115400A (en) Short-circuiter
AU2804600A (en) Arylaminoalkylamides
AU6440900A (en) Homogentisate-dioxygenase
AU2699800A (en) Organoceramics
AU6098300A (en) Follistatin-3
AU4916900A (en) Benzofuranylsulfonates
AU4561600A (en) Benzofuranylaminoalcohols
AU1558300A (en) 1-cycloalkylpyrazoyl-benzoyl derivatives
AU6262300A (en) Indolinylamide derivatives
AU1901801A (en) Glucofuranoses
AU5666800A (en) Difuropyrone derivatives
AU2028401A (en) 3-methyl-chromane or thiochromane derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase